Stressgen (VSE: SSB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stressgen (VSE: SSB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Heat Shock who wrote (114)	3/17/2000 4:53:00 PM
From: Heat Shock	Read Replies (1) of 236

To all: various StressGen clinical trials are moving ahead nicely: StressGen Biotechnologies Announces Initiation of Phase II Study with HspE7 newswire.ca StressGen announced the initial enrollment of patients in its phase II study in women with high-grade cervical dysplasia. The trial will determine if the treatment can reduce the grade of dysplasia or eliminate the dysplastic cells. Another Phase II study is underway in immunocompetent male and female patients with high-grade anal dysplasia. This trial program is progressing well and accrual for the interim analysis has been completed on schedule. The Company also plans to initiate a Phase II study in cervical cancer patients, a distinct patient population from cervical dysplasia patients, in the second quarter of 2000. Heat.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next